UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Astbury S, Reynolds CJ, Butler DK, Munoz-Sandoval DC, Lin K-M, Pieper FP, Otter A, Kouraki A, Cusin L, Nightingale J, Vijay A, Craxford S, Aithal GP, Tighe PJ, Gibbons JM, Pade C, Joy G, Maini M, Chain B, Semper A, Brooks T, Ollivere BJ, McKnight Á, Noursadeghi M, Treibel TA, Manisty C, Moon JC, COVIDsortium investigators , Valdes AM, Boyton RJ, Altmann DM
  • Publication date:
    01/05/2022
  • Journal:
    Immunology
  • Status:
    Published
  • Country:
    England
  • Language:
    eng
  • Keywords:
    COVID-19, HLA, SARS-CoV-2, T cell immunity, immunogenetics, vaccine
Abstract
SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection, to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variation. Human leukocyte antigen (HLA) polymorphisms may influence immune response and disease outcome. We investigated the association of HLAII alleles with case definition symptomatic COVID-19, virus-specific antibody and T cell immunity. 1,364 UK healthcare workers (HCW) were recruited during the first U.K. SARS-CoV-2 wave and analyzed longitudinally, encompassing regular PCR screening for infection, symptom reporting, imputation of HLAII genotype and analysis for antibody and T cell responses to nucleoprotein (N) and spike (S). Of 272 (20%) HCW who seroconverted, the presence of HLA-DRB1*13:02 was associated with a 6.7-fold increased risk of case definition symptomatic COVID-19. In terms of immune responsiveness, HLA-DRB1*15:02 was associated with lower nucleocapsid T cell responses. There was no association between DRB1 alleles and anti-spike antibody titres after two COVID vaccine doses. However, HLA DRB1*15:01 was associated with increased spike T cell responses following both first and second dose vaccination. Trial registration - NCT04318314 and ISRCTN15677965.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers Show More
Author
Div of Medicine
Author
MRC Unit for Lifelong Hlth & Ageing
Author
Div of Infection & Immunity
Author
Clinical Science
Author
Div of Infection & Immunity
Author
Div of Medicine
Author
Institute of Cardiovascular Science
Author
Population Science & Experimental Medicine
Author
Clinical Science
Author
Div of Infection & Immunity
Author
Clinical Science
Author
Clinical Science
Author
Div of Infection & Immunity
Author
Div of Infection & Immunity
Author
Clinical Science
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by